Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·When does a brain signal become usable for device control?
Review or Meta-AnalysisA 2021 review explains how sensors, control cues and calibration affect whether brain-controlled devices can respond reliably for different people and tasks.
-
Evidence date ·Could one engineered T cell target liver tumors and blood-vessel cells?
Peer-Reviewed PaperEngineered T cells killed CD105-rich liver-cancer and vessel-lining cells in lab tests, then slowed implanted liver tumors in two mouse models.
-
Evidence date ·What can a diagnosis code reveal about an immunotherapy reaction?
Review or Meta-AnalysisOf 174 patients with chart-identified reactions, 49 had no reflecting code and 31 had codes before treatment; 459 had suggestive codes but no chart-identified reaction.
-
Evidence date ·Can profiling bile duct tumors outside the liver sharpen the search for treatment?
Review or Meta-AnalysisA 2021 review finds potential drug targets in about one-quarter of extrahepatic bile duct tumors, while mixed-site trials make treatment results harder to interpret.
-
Evidence date ·What changed when immune checkpoint drugs joined cancer treatment?
Review or Meta-AnalysisA 19-trial review found better survival and response rates with added checkpoint drugs, while time to response showed no significant difference and severe side effects rose slightly.
-
Evidence date ·US studies used different benchmarks for advanced lung cancer drugs
Review or Meta-AnalysisIn 28 US lung cancer drug analyses, median cost-effectiveness thresholds were $150,000 in industry-supported studies and $100,000 in nonprofit-supported studies.
-
Evidence date ·What can remain after high-grade glioma treatment?
Review or Meta-AnalysisA 2021 review explains how glioblastoma cells can extend beyond the visible tumor and vary within it, complicating surgery and efforts to tailor treatment.
-
Evidence date ·A tumor’s response to immune treatment is a changing story
Review or Meta-AnalysisA melanoma study linked a week-four drop in tumor mutation count with response to nivolumab. The review also traces how tumors can evade immune attack.
-
Evidence date ·Why does MSI-high matter more in some colorectal cancer stages?
Review or Meta-AnalysisA 2021 meta-analysis linked high microsatellite instability with less spread overall; survival differences were clearest in stages II and III.
-
Evidence date ·Why is holding adenoid cystic carcinoma steady easier than making it respond?
Review or Meta-AnalysisA 2021 review describes mostly stable disease across adenoid cystic carcinoma treatments and points to weak immune recognition as a barrier to checkpoint drugs.